ISCHEMIC HEART DISEASE: PATHOGENESIS AND TREATMENT

Authors:

AXMADULINA GALIYA MARSOVNA

ISCHEMIC HEART DISEASE: PATHOGENESIS AND TREATMENT

(Monograph)

Compilied by

AXMADULINA GALIYA MARSOVNA

2025

Ischemic Heart Disease: Pathogenesis and Treatment presents a concise yet comprehensive synthesis of contemporary knowledge on the world's leading cause of death. After tracing the historical evolution of coronary theory, the monograph examines current mechanistic insights—from endothelial dysfunction and oxidative stress to immune-metabolic crosstalk, clonal haematopoiesis, and gut–heart signalling. Genomic, epigenetic, and proteomic findings are linked to plaque initiation, progression, and destabilisation, providing a coherent "molecule-to-patient" narrative.

Diagnostic advances are reviewed next, including high-resolution coronary CT, stress perfusion MRI, hybrid PET/CT, and artificial-intelligence risk scores that refine stratification beyond traditional factors. Therapeutic chapters integrate pharmacology, intervention, and rehabilitation: precision antiplatelet and lipid-lowering regimens (PCSK9 inhibitors, inclisiran), anti-inflammatory strategies targeting IL-1β and NLRP3, cardioprotective GLP-1R and SGLT2 modulators, regenerative cell-based approaches, and state-of-the-art percutaneous and hybrid surgical revascularisation techniques. Special attention is paid to sex- and age-specific phenotypes, multimorbidity, and implementation in resource-limited settings.

Throughout, the book emphasises personalised, guideline-concordant care, interdisciplinary collaboration, and lifestyle optimisation grounded in behavioural science. Richly illustrated and extensively referenced, it serves clinicians, researchers, and policy-makers seeking an integrated view of ischemic heart disease biology and the evolving therapeutic arsenal.

Chief Editor:

A.R. Muradimova, PhD in Medical Sciences, Dotcent

Reviewers:

Umarov O.M	**Head of the Department of Dentistry and otorhinolaryngology, PhD, FMIPH**
Ismailov M.M.	**Chief Physician of the Ferghana Regional Dental Clinic**

UDK 614.7-628.1.032(575.121):613.31

Ischemic heart disease: pathogenesis and treatment Monograph / Axmadulina Galiya Marsovna. 2025. -65 p.

MINISTRY OF HIGHER EDUCATION, SCIENCE AND INNOVATIONS
OF THE REPUBLIC OF UZBEKISTAN

MINISTRY OF HEALTH CARE OF THE REPUBLIC OF UZBEKISTAN

FERGANA MEDICAL INSTITUTE OF PUBLIC HEALTH

«APPROVED»

Rector of the Fergana Medical Institute
of Public Health, DSc, professor
A.Sidikov

« 31 » 05 —2025 y.

Axmadulina G.M.

ISCHEMIC HEART DISEASE: PATHOGENESIS AND TREATMENT

(Monograph)

Ferghana -2025 y.

CONTENTS

ABSTRACT

This monograph provides a comprehensive analysis of the pathogenesis, clinical course, and pharmacotherapeutic approaches to ischemic heart disease (IHD). IHD, a condition resulting from inadequate blood supply to the heart muscle or complete cessation of blood flow, can lead to conditions such as myocardial infarction, angina, and other cardiovascular disorders. The monograph delves into the molecular and cellular mechanisms involved in the development of IHD, primarily focusing on atherosclerosis and the narrowing of blood vessels. It describes key clinical features, symptoms, diagnostic methods, and the latest treatment strategies. Additionally, the effectiveness of pharmacotherapy approaches, including the role of angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, statins, and thrombolytic agents, is explored in detail.

This work not only presents scientific analysis and theoretical foundations but also offers practical advice for clinical practice. It emphasizes the prevention of IHD, new therapeutic approaches, and the effectiveness of various medications in managing the disease. This monograph serves as a valuable resource for medical professionals, cardiologists, and students, as well as anyone seeking in-depth knowledge about ischemic heart disease.

ANNOTATSIYA

Ushbu monografiya ishemik yurak kasalligi (IYK)ning patogenezini, klinik kechishini va davolashda qoʻllaniladigan farmakoterapiya yondashuvlarini chuqur tahlil qiladi. IYK – yurakning qon bilan taʼminlanishining yomonlashuvi yoki toʻliq toʻxtab qolishi natijasida yuzaga keladigan kasallik boʻlib, bu holat miokard infarkti, stenokardiya va boshqa yurak-tomir kasalliklariga olib kelishi mumkin. Monografiyada IYK ning rivojlanishidagi molekulyar va hujayrali mexanizmlar, asosan ateroskleroz va qon tomirlarning torayishi bilan bogʻliq jarayonlar batafsil yoritiladi. Klinik kechishdagi muhim jihatlar, simptomlar, diagnostik usullar va zamonaviy davolash yondashuvlari taʼriflanadi. Bundan tashqari, farmakoterapiya yondashuvlarining samaradorligi va yangi davolash metodlari, shu jumladan,

angiotenzin-konvertatsiya fermenti (ACE) inhibitori, beta-blokerlar, statinlar va trombolitik vositalar kabi dori vositalarining roli o'rganiladi.

Monografiya nafaqat ilmiy tahlil va nazariy asoslarni, balki klinik praktika uchun amaliy maslahatlarni ham taqdim etadi. U IYK ning profilaktikasi, davolashda yangi yondashuvlar va dori vositalarining samaradorligini o'rganishga qaratilgan. Kitob tibbiyot mutaxassislari, kardiologlar va talabalar uchun foydali bo'lib, ishemik yurak kasalligi bo'yicha yanada chuqurroq bilim olishni istagan barcha uchun manba bo'lishi mumkin.

АННОТАЦИЯ

Данная монография представляет собой всесторонний анализ патогенеза, клинического течения и фармакотерапевтических подходов при ишемической болезни сердца (ИБС). ИБС – это заболевание, вызванное недостаточным кровоснабжением сердечной мышцы или полным прекращением кровотока, что может привести к таким состояниям, как инфаркт миокарда, стенокардия и другим сердечно-сосудистым заболеваниям. Монография подробно рассматривает молекулярные и клеточные механизмы, связанные с развитием ИБС, в первую очередь фокусируясь на атеросклерозе и сужении сосудов. Описание ключевых клинических признаков, симптомов, диагностических методов и современных методов лечения также представлено в работе. Кроме того, подробно исследуется эффективность фармакотерапевтических подходов, включая роль ингибиторов ангиотензин-превращающего фермента (АПФ), бета-блокаторов, статинов и тромболитических агентов.

Монография не только представляет научный анализ и теоретические основы, но и дает практические рекомендации для клинической практики. Особое внимание уделяется профилактике ИБС, новым терапевтическим подходам и эффективности различных медикаментов в лечении заболевания. Эта работа будет полезна для медицинских специалистов, кардиологов,

студентов и всех, кто заинтересован в глубоком изучении ишемической болезни сердца.

INTRODUCTION

Ischemic heart disease (IHD) is one of the leading causes of morbidity and mortality worldwide. Characterized by the insufficient blood flow to the heart muscle, IHD is primarily a result of atherosclerosis, coronary artery disease, and myocardial ischemia. As the global population ages and lifestyle-related risk factors such as hypertension, smoking, obesity, and diabetes become more prevalent, the incidence of IHD continues to rise, posing a significant challenge to public health systems and healthcare providers. The pathogenesis of IHD is multifaceted, involving complex interactions between genetic predisposition, environmental factors, and the response of vascular structures to these stimuli. Atherosclerosis, the most common cause of IHD, leads to the narrowing and hardening of coronary arteries, which in turn impairs the supply of oxygen and nutrients to the heart muscle. As the disease progresses, ischemia can lead to serious complications such as angina pectoris, myocardial infarction, arrhythmias, and, in severe cases, heart failure.

This monograph aims to provide an in-depth understanding of the pathophysiological mechanisms underlying IHD, exploring the cellular and molecular processes involved in the development of coronary artery disease. In addition, it will review the clinical course of IHD, highlighting the symptoms, diagnostic approaches, and the latest advancements in the treatment and management of the disease. Pharmacotherapy plays a central role in the management of IHD, with various drug classes, including antiplatelet agents, statins, beta-blockers, and angiotensin-converting enzyme (ACE) inhibitors, being crucial in reducing the risk of complications and improving patient outcomes.

Through a comprehensive analysis of current scientific research, this monograph seeks to inform clinicians, researchers, and students of the latest advancements in the diagnosis and management of ischemic heart disease, emphasizing the importance of early detection, prevention, and individualized treatment strategies. Understanding the intricate mechanisms of IHD and the

pharmacological options available is vital for improving patient care and reducing the burden of cardiovascular diseases globally.

Chapter I. PATHOGENESIS OF ISCHEMIC HEART DISEASE

1.1. Mechanisms of development of ischemic heart disease

Ischemic heart disease (IHD) is primarily caused by the atherosclerosis of coronary arteries, accompanied by their spasms and the formation of thrombi, leading to an inadequate supply of oxygen to the myocardium. The inability to meet the oxygen demands of the heart muscle due to insufficient blood flow is the hallmark of ischemia. Atherosclerotic changes in the coronary arteries are not only the leading cause of IHD in older adults but are also increasingly observed in younger individuals, including men under the age of 40. The progression of atherosclerosis in the coronary arteries leads to the development of either transient or persistent ischemic processes in the areas that these arteries supply with blood.

The degree of atherosclerotic changes varies, with approximately 30% of patients having one artery affected, one-third of patients experiencing damage in two arteries, and the remaining cases involving three coronary arteries. The process of atherosclerosis typically starts with the left coronary artery, specifically the anterior interventricular branch, followed by the circumflex branch, and then the right coronary artery. Some studies suggest that atherosclerosis is more commonly observed in the first 6 cm of the coronary arteries.

The formation of atherosclerotic plaques in the coronary arteries restricts blood flow and can lead to the rupture of these plaques, forming a thrombus that further obstructs blood flow. This obstruction causes an acute reduction in oxygen delivery to the myocardium, leading to myocardial ischemia. In severe cases, up to 75% or more of the vessel may be narrowed due to atherosclerotic changes, as identified through coronary angiography. In some instances, patients with IHD show no significant atherosclerotic narrowing in the major proximal coronary arteries, yet they may experience transient myocardial ischemia. This condition, referred to as "X syndrome," is characterized by damage to small peripheral coronary vessels that remain undetectable by conventional coronary angiography.

On a molecular level, myocardial ischemia begins with endothelial dysfunction. This dysfunction occurs as a result of the accumulation of low-density lipoproteins (LDL) in the arterial walls, which undergo oxidation and induce an inflammatory response. This inflammation leads to the recruitment of immune cells, such as monocytes and T-lymphocytes, that infiltrate the arterial walls and contribute to plaque formation. Over time, the plaque grows, and smooth muscle cells proliferate, creating a fibrous cap that covers the lipid core of the plaque. As the plaque enlarges, it increases the likelihood of rupture, which exposes the thrombogenic lipid core to the bloodstream. This triggers the formation of a blood clot (thrombus), which can completely occlude the affected coronary artery, resulting in myocardial ischemia and potentially leading to myocardial infarction (heart attack). The ischemic process in the myocardium causes a cascade of metabolic disturbances in cardiomyocytes (heart muscle cells). ATP production decreases as the mitochondria become less efficient due to the lack of oxygen. This ATP depletion disrupts the function of ion pumps in the cell, leading to an accumulation of sodium and calcium ions inside the cells.

These ionic imbalances further disrupt cellular homeostasis, causing cell swelling and damage. The increased calcium levels activate enzymes such as proteases and phospholipases, which damage cell membranes and promote cell death, either through necrosis or apoptosis. The accumulation of metabolic byproducts, including lactic acid, exacerbates the acidic environment within ischemic tissue, compounding cellular injury and impairing cellular function. This metabolic derangement leads to a reduction in myocardial contractility, contributing to the clinical manifestation of heart failure. The molecular and cellular mechanisms of myocardial ischemia involve the initiation of atherosclerosis, followed by plaque formation, rupture, and thrombus formation, which lead to the obstruction of blood flow and insufficient oxygen supply to the myocardium. These events result in cellular and metabolic disturbances in cardiomyocytes, ultimately leading to myocardial dysfunction and the clinical symptoms associated with IHD. Understanding these mechanisms provides

insights into potential therapeutic strategies aimed at improving outcomes for patients with ischemic heart disease.

Atherosclerosis plays a central role in the pathogenesis of ischemic heart disease (IHD). It is a complex, chronic process that involves the accumulation of lipids, inflammatory cells, and smooth muscle cells within the arterial walls, leading to the formation of plaques. Over time, these plaques narrow the arteries and impede blood flow, contributing to the development of ischemia in the myocardial tissue. The progression of atherosclerosis is particularly dangerous in coronary arteries, where it reduces the ability of the heart to receive adequate oxygen and nutrients, thus triggering a cascade of cellular events that can lead to myocardial infarction (heart attack).

Picture 1. *Atherosclerosis and artery blockage, main villain in heart attack*

Endothelial dysfunction is one of the earliest and most critical events in the development of atherosclerosis. The endothelium, which lines the blood vessels, plays a vital role in maintaining vascular homeostasis by regulating vascular tone,

blood flow, and permeability. When endothelial cells are damaged due to various risk factors, such as high blood pressure, smoking, high cholesterol levels, or diabetes, they become dysfunctional. This dysfunction leads to an imbalance in the production of vasodilators (such as nitric oxide) and vasoconstrictors (such as endothelin), which increases vascular tone and promotes the development of atherosclerotic plaques.

Endothelial dysfunction also facilitates the adhesion of leukocytes and platelets to the vessel wall. This increases the likelihood of inflammatory responses, which further promote the formation of atherosclerotic plaques. In addition, dysfunctional endothelial cells produce increased amounts of reactive oxygen species (ROS), contributing to oxidative stress, which further damages the endothelium and accelerates the atherosclerotic process. As the endothelial barrier becomes compromised, it allows lipids, especially oxidized low-density lipoproteins (LDL), to penetrate the arterial wall, further initiating the process of plaque formation.

Thrombosis, or the formation of blood clots, is another key factor in the progression of ischemic heart disease. As an atherosclerotic plaque grows, its fibrous cap can rupture or become ulcerated, exposing the lipid-rich core of the plaque to the bloodstream. This triggers the coagulation cascade and leads to platelet aggregation and fibrin formation, creating a thrombus at the site of plaque rupture. This thrombus can rapidly occlude the artery, blocking blood flow to the myocardium and causing myocardial ischemia or infarction.

In the context of ischemic heart disease, thrombosis often occurs in the presence of already compromised coronary vessels due to pre-existing atherosclerosis. The clot formed on the ruptured plaque may obstruct a major coronary artery, leading to a sudden reduction or complete cessation of blood flow. This is often referred to as acute coronary syndrome (ACS), which includes conditions such as unstable angina, non-ST elevation myocardial infarction (NSTEMI), and ST elevation myocardial infarction (STEMI). In these conditions,

thrombosis plays a pivotal role in the acute ischemic event, highlighting the need for rapid intervention to dissolve the clot and restore blood flow to the heart muscle.

In summary, the pathogenesis of ischemic heart disease is strongly influenced by atherosclerosis, endothelial dysfunction, and thrombosis. Endothelial dysfunction initiates the atherosclerotic process and facilitates plaque formation, while thrombosis exacerbates the consequences of this process by leading to the acute obstruction of coronary arteries. These interconnected processes contribute significantly to the development of ischemic heart disease and its clinical manifestations, such as myocardial ischemia, infarction, and heart failure. Understanding the molecular mechanisms behind these phenomena is essential for developing therapeutic strategies to prevent and treat ischemic heart disease.

1.2. Atherosclerosis and the narrowing of blood vessels

Atherosclerosis is a chronic condition that involves the progressive thickening and stiffening of the arterial walls due to the accumulation of lipids, cholesterol, and other substances. This pathological process significantly impacts the coronary arteries, leading to the development of ischemic heart disease (IHD).

The stages of atherosclerosis are characterized by the gradual accumulation of plaque within the arterial lumen, which narrows the arteries and impedes blood flow, thereby compromising the delivery of oxygen and nutrients to vital organs, including the myocardium.

Picture 2. *Atherosclerosis stages vector illustration on white background. Healthy and unhealthy arteries.*

The process of atherosclerosis begins with the injury to the endothelium, the inner lining of blood vessels, which allows the infiltration of low-density

lipoproteins (LDL) into the arterial wall. These LDL particles are oxidized within the wall, triggering an inflammatory response that attracts immune cells such as macrophages. These macrophages attempt to clear the oxidized LDL but instead engulf it, becoming foam cells. This accumulation of foam cells leads to the formation of a fatty streak, the earliest visible sign of atherosclerosis.

As the process progresses, smooth muscle cells proliferate and migrate from the media (middle layer of the artery) into the intima (inner layer), where they synthesize extracellular matrix proteins such as collagen. This leads to the formation of a fibrous cap over the lipid-rich core of the plaque. Over time, the plaque enlarges, narrowing the artery and further restricting blood flow. The narrowing of the blood vessel causes increased pressure within the artery and forces the heart to work harder to pump blood through the constricted vessel. In severe cases, the fibrous cap of the plaque can rupture, exposing the thrombogenic core to the circulating blood. This triggers the clotting cascade, resulting in the formation of a thrombus (blood clot) that can completely occlude the artery. This sudden occlusion of blood flow can lead to an acute ischemic event, such as myocardial infarction (heart attack), highlighting the importance of timely intervention to restore blood flow.

Pathological changes in the blood vessels during atherosclerosis, such as the thickening of the arterial wall and plaque formation, directly contribute to the development of ischemic heart disease. The narrowing of the arteries increases vascular resistance and impedes the efficient flow of blood. In the coronary arteries, this reduced blood flow results in myocardial ischemia, which, if left untreated, can progress to myocardial infarction. In addition to the mechanical obstruction caused by atherosclerotic plaques, there are functional changes in the blood vessels themselves. The endothelium, which plays a crucial role in regulating blood flow and vascular tone, becomes dysfunctional due to the accumulation of inflammatory mediators, oxidative stress, and the presence of advanced glycation end products (AGEs). Endothelial dysfunction leads to an

imbalance between vasodilators (such as nitric oxide) and vasoconstrictors (such as endothelin), which can result in vasoconstriction, further exacerbating ischemia.

Several factors contribute to the development of atherosclerosis, including lipid abnormalities, elevated levels of homocysteine and oxidative stress.

1. **Lipids**: The accumulation of lipids, particularly low-density lipoprotein (LDL) cholesterol, in the arterial wall is a primary driver of atherosclerosis. Oxidized LDL is particularly harmful, as it triggers an inflammatory response and promotes the formation of foam cells. High levels of total cholesterol and LDL cholesterol, combined with low levels of high-density lipoprotein (HDL) cholesterol, increase the risk of atherosclerosis and, consequently, ischemic heart disease.

2. **Homocysteine levels**: Homocysteine is an amino acid that, at elevated levels, has been shown to damage the endothelium, increase oxidative stress, and promote the formation of plaques in the arteries. High levels of homocysteine are often associated with genetic factors, dietary deficiencies (particularly folic acid, vitamin B6, and B12), and certain medical conditions. Elevated homocysteine levels are considered an independent risk factor for atherosclerosis and ischemic heart disease.

3. **Oxidative stress**: Oxidative stress plays a critical role in the initiation and progression of atherosclerosis. It refers to an imbalance between the production of reactive oxygen species (ROS) and the body's ability to neutralize them with antioxidants. ROS, particularly those generated by oxidized LDL, can damage endothelial cells, promote inflammation, and contribute to the formation of atherosclerotic plaques. Oxidative stress also accelerates the process of endothelial dysfunction and enhances the instability of plaques, making them more likely to rupture.

The development of atherosclerosis and the narrowing of blood vessels are key contributors to ischemic heart disease. The stages of atherosclerosis, from

endothelial dysfunction and lipid accumulation to plaque formation and rupture, play a central role in the pathogenesis of IHD. Factors such as elevated lipid levels, homocysteine, and oxidative stress further accelerate the progression of the disease. Understanding these mechanisms is essential for identifying at-risk populations and developing effective therapeutic strategies to prevent and treat ischemic heart disease.

1.3. The influence of genetic and environmental factors on IHD

Ischemic heart disease (IHD) is a multifactorial condition, with both genetic and environmental factors playing crucial roles in its development. Understanding how these factors contribute to the onset and progression of IHD is essential for better risk prediction, prevention strategies, and therapeutic interventions. Genetic factors are considered one of the most significant contributors to the development of ischemic heart disease. Studies have shown that individuals with a family history of heart disease are at a higher risk of developing IHD themselves. This familial predisposition can be attributed to the inheritance of specific genetic traits that influence cardiovascular risk factors, such as lipid metabolism, blood pressure regulation, and the inflammatory response. One of the key genetic factors associated with IHD is the presence of certain polymorphisms in genes related to cholesterol metabolism, particularly the apolipoprotein E (APOE) gene. Variants of this gene can affect the levels of low-density lipoprotein (LDL) cholesterol, a major contributor to atherosclerosis. Additionally, genetic mutations that affect the function of enzymes involved in the metabolism of lipids, such as the lipoprotein lipase gene (LPL), have been linked to an increased risk of developing atherosclerosis and IHD.

Apart from lipid metabolism, other genetic factors, such as those influencing blood clotting and the inflammatory response, can also contribute to IHD. For example, mutations in genes that regulate blood clotting factors, such as the factor V Leiden mutation or prothrombin gene mutation, can increase the likelihood of thrombosis, a key event in the development of myocardial infarction. Genetic

predisposition to inflammation, particularly through variations in cytokine genes, can also play a role in the progression of atherosclerotic plaques and their instability, leading to increased cardiovascular risk.

While genetic factors contribute significantly to IHD risk, environmental factors play an equally important role. Among these factors, lifestyle choices, including diet, physical activity, and stress levels, are some of the most modifiable and influential determinants of cardiovascular health.

Dietary factors: Diet is a key environmental factor influencing the development of IHD. A diet high in saturated fats, trans fats, and cholesterol contributes to the accumulation of lipids in the blood, particularly LDL cholesterol, which promotes the formation of atherosclerotic plaques in the arteries. Conversely, diets rich in fruits, vegetables, whole grains, and healthy fats (such as those found in olive oil and fatty fish) have been shown to reduce the risk of atherosclerosis and heart disease. Nutritional factors, such as increased intake of antioxidants and fiber, can also help mitigate oxidative stress and inflammation, further reducing IHD risk.

Table 1. *Dietary factors and their effects on IHD risk*

Dietary factor	Effect on IHD risk	Food examples
High in saturated fats	Increases risk by promoting accumulation of lipids, particularly LDL cholesterol, leading to atherosclerosis.	Butter, fatty meats, cheese
High in trans fats	Increases risk by raising LDL cholesterol levels and promoting plaque formation in arteries.	Processed foods, fried foods, baked goods
High in cholesterol	Increases risk by contributing to elevated LDL cholesterol levels.	Egg yolks, fatty meats, high-fat dairy

Dietary factor	Effect on IHD risk	Food examples
		products
Rich in fruits and vegetables	Reduces risk by providing vitamins, minerals, and antioxidants that promote cardiovascular health.	Apples, oranges, spinach, berries
Rich in whole grains	Reduces risk by providing fiber that helps lower cholesterol levels and improves heart health.	Oats, barley, quinoa, brown rice
Rich in healthy fats (Olive oil, Fatty fish)	Reduces risk by increasing HDL cholesterol and reducing LDL cholesterol, reducing plaque formation.	Olive oil, fatty fish (salmon, mackerel), nuts
Increased antioxidants	Reduces risk by counteracting oxidative stress and inflammation in the arteries.	Berries, green leafy vegetables, nuts, seeds
Increased fiber	Reduces risk by promoting a healthy digestive system and lowering cholesterol levels.	Whole grains, beans, legumes, fruits

This table summarizes how different dietary factors influence the risk of ischemic heart disease (IHD), along with food examples for each factor.

Physical activity: Regular physical activity is another crucial factor in preventing and managing IHD. Physical exercise improves cardiovascular health by increasing heart efficiency, reducing blood pressure, and enhancing blood flow. Moreover, exercise helps maintain a healthy weight, which is vital for reducing risk factors such as hypertension, diabetes, and obesity. It also promotes healthy cholesterol levels by increasing high-density lipoprotein (HDL) cholesterol, which helps remove excess LDL cholesterol from the bloodstream.

Stress: Chronic stress is recognized as a significant environmental factor that contributes to the development and exacerbation of IHD. Stress activates the sympathetic nervous system, leading to the release of stress hormones such as cortisol and adrenaline. These hormones can increase heart rate and blood pressure, contributing to the wear and tear of the arterial walls and promoting the development of atherosclerosis. Additionally, stress can lead to unhealthy behaviors, such as overeating, smoking, or physical inactivity, which further elevate cardiovascular risk.

The identification of risk factors for ischemic heart disease is crucial for early intervention and prevention. These risk factors can be classified into modifiable and non-modifiable categories. Modifiable risk factors include high blood pressure, high cholesterol levels, smoking, diabetes, poor diet, physical inactivity, and excessive alcohol consumption. Non-modifiable risk factors include age, gender, and family history of cardiovascular disease.

By assessing these risk factors, healthcare professionals can better predict the likelihood of IHD development and take proactive measures to reduce the risk in at-risk populations. For example, individuals with a family history of heart disease or those with specific genetic markers may benefit from early lifestyle modifications and regular screening for blood pressure, cholesterol, and glucose levels. On the other hand, environmental factors such as poor diet, lack of exercise, and stress can be targeted through public health campaigns and individual counseling to prevent the onset of IHD. Ischemic heart disease is influenced by a combination of genetic and environmental factors. While genetic predisposition plays a significant role in determining an individual's susceptibility to IHD, modifiable environmental factors, such as diet, exercise, and stress management, provide opportunities for intervention and prevention. By understanding and addressing both genetic and environmental risk factors, healthcare providers can better manage and reduce the burden of ischemic heart disease on individuals and populations.

Chapter II. CLINICAL COURSE OF ISCHEMIC HEART DISEASE

2.1. Clinical signs of cardiac ischemia

The clinical course of ischemic heart disease encompasses the spectrum of manifestations that result from inadequate coronary blood flow and subsequent myocardial oxygen deprivation. These manifestations range from transient, asymptomatic episodes of ischemia to acute presentations such as angina pectoris and myocardial infarction, as well as the chronic sequelae of repeated ischemic insults. Understanding the progression of clinical signs and symptoms is essential for early recognition, timely intervention, and optimal management of patients at risk.

In this chapter, we first examine the **clinical signs of cardiac ischemia**, exploring how they present in various stages of disease and how subtle changes in patient history, physical examination, and simple diagnostic tests can herald significant underlying pathology. This foundation allows us to appreciate the ways in which ischemia can manifest, from silent episodes to overt anginal pain, and sets the stage for subsequent discussion of diagnostic modalities and treatment strategies.

"There are a number of classifications of coronary heart disease, and in practice, the IV the classification adopted at the congress and presented in Table 2 is applied.

Table 2. *Classification of Ischemic Heart Disease*

№	Classification element
1	Sudden coronary death (primary cardiac arrest)
2	Angina pectoris
	2.1 Stable exertional angina (with indication of functional classes I-IV)

№	Classification element
	2.2 Unstable angina
	- Newly developed angina
	- Progressive angina
	- Angiospastic angina (spontaneous, variant, Prinzmetal type)
	- Early post-infarction angina
	- Post-surgical angina (after cardiac surgery)
3	Painless myocardial ischemia
4	Microvascular angina ("X syndrome")
5	Myocardial infarction
	- With K wave – KMI
	- Without K wave – NKMI
6	Post-infarction cardiosclerosis
7	Cardiac arrhythmias (indicating type)
8	Heart failure (indicating form and stage)

This classification separately lists the types of unstable angina, which represent an intermediate state between stable angina and myocardial infarction (MI) and are characterized by a higher risk of mortality (3-4% in stable angina, 10-20% in unstable angina). In addition, forms of IHD not included in modern classifications but representing early stages of the disease (unstable angina, small- and large-focal MI), which often share common morphological changes (plaque rupture, coronary thrombosis, transformation from one clinical form to another –

for example, from unstable angina to MI or death), must also be recognized under the broader category of acute coronary syndrome"[1].

Ischemic heart disease most frequently presents as angina pectoris, arising when atherosclerotic narrowing of major coronary arteries impairs the ability of small, resistance-level arterioles to dilate appropriately in response to increases in myocardial oxygen demand. Although exertional (stable) angina is the most common form, any factor that acutely elevates the heart's workload – such as tachycardia, heightened contractility, elevated afterload or preload, emotional stress, or neurohormonal activation – can precipitate ischemic chest pain. In roughly 40% of men and 56% of women with ischemic heart disease, the condition first manifests as stable exertional angina, often progressing insidiously over time.

Angina pectoris

Angina pectoris arises when an imbalance develops between myocardial oxygen supply and demand, most often owing to atherosclerotic narrowing of the epicardial coronary arteries. In a healthy heart, small resistance arterioles dilate to increase blood flow during exertion; however, when fixed plaques occupy 50-70 percent of the lumen, this compensatory mechanism fails. As heart rate accelerates, contractility increases under sympathetic stimulation, or afterload and preload rise, myocardial oxygen requirements outpace delivery and provoke the characteristic chest discomfort of angina.

Patients typically describe anginal pain as a deep, squeezing, burning, or pressing sensation felt behind the sternum. It often radiates to the left shoulder and arm, jaw, neck, or epigastrium, and may occasionally extend into the back or right side of the chest. Episodes tend to last between one and ten minutes and are relieved promptly by rest or sublingual nitroglycerin. Sweating, shortness of breath, nausea, lightheadedness, and a sense of impending doom frequently accompany the pain.

---

[1] A.Gadayev. Ichki kasalliklar. – T.: "Turon zamin ziyo". 2016. – 250-b.

Picture 3. *Angina pectoris.*

Although most commonly precipitated by physical activity - such as walking uphill, climbing stairs, or lifting heavy objects - angina may also occur during emotional stress, exposure to cold, or following heavy meals. Any condition that increases heart rate (tachycardia), enhances contractile force, elevates systemic blood pressure, or raises venous return can trigger ischemia by further increasing myocardial work. Variant (Prinzmetal) angina, in contrast, is caused by transient spasm of a coronary artery and may occur at rest; it often produces brief ST-segment elevation on ECG and responds well to vasodilators such as calcium channel blockers.

The evaluation of a patient with suspected angina begins with a careful history. Key features include the nature, location, duration, and triggers of chest discomfort, as well as factors that relieve it. A resting electrocardiogram may reveal previous infarction (Q-waves) or non-specific ST-T changes, but it is often normal between episodes. Exercise or pharmacologic stress testing allows assessment of ischemia under controlled conditions, identifying ECG changes, wall motion abnormalities on echocardiography, or perfusion defects on nuclear imaging. Noninvasive anatomic assessment with coronary computed tomography angiography can reveal plaque burden and luminal narrowing, while invasive

coronary angiography remains the gold standard for defining stenosis and guiding revascularization decisions.

Medical management aims first to alleviate symptoms and then to modify long-term risk. Sublingual nitroglycerin offers rapid relief by venodilation and modest coronary dilation. β-Blockers reduce heart rate and contractility, lowering oxygen demand and improving exercise tolerance; they are considered first-line therapy in stable angina. Calcium channel blockers provide additional relief, particularly in variant angina, by preventing vasospasm and reducing afterload. When symptoms persist despite these measures, ranolazine - an agent that reduces late sodium current - may be added to improve diastolic function and lessen ischemia.

Concurrent risk factor modification is crucial. High-intensity statin therapy slows plaque progression and stabilizes vulnerable lesions. Blood pressure control with ACE inhibitors or angiotensin receptor blockers mitigates afterload and offers cardioprotective benefits. Smoking cessation, a heart-healthy diet rich in fruits, vegetables, whole grains, and healthy fats, as well as regular moderate exercise, lower cardiovascular risk. Aspirin reduces thrombotic complications by inhibiting platelet aggregation, and dual antiplatelet therapy is indicated after stenting or in high-risk unstable patients.

Prognosis in stable angina depends on the severity of coronary disease, left ventricular function, and the presence of comorbidities. Annual mortality rates for well-controlled stable angina remain low (1-2 percent), whereas unstable angina carries a substantially higher short-term risk of myocardial infarction and death if not managed urgently. Revascularization - either percutaneous coronary intervention or coronary artery bypass grafting – is considered when medical therapy fails to control symptoms or when high-risk anatomical lesions are identified.

Angina pectoris reflects underlying coronary atherosclerosis and requires an integrated approach: accurate history and targeted diagnostics to confirm ischemia,

symptom-directed pharmacotherapy, aggressive modification of risk factors, and timely consideration of revascularization. Through this multifaceted strategy, clinicians can relieve symptoms, improve quality of life, and reduce the long-term complications of ischemic heart disease.

Myocardial Infarction (MI)

Myocardial infarction occurs when an atherosclerotic plaque within a coronary artery ruptures or erodes, triggering the rapid formation of a thrombus that abruptly occludes blood flow. This sudden obstruction deprives downstream myocardium of oxygen and nutrients, leading to ischemic necrosis within minutes. Although collateral vessels can sometimes provide partial perfusion, they rarely compensate fully in the acute setting, and irreversible myocardial injury begins as early as twenty to thirty minutes after occlusion.

Clinically, patients with myocardial infarction often describe a prolonged, severe chest discomfort, distinguishing it from the transient pain of angina. The sensation may be described as crushing, constricting, or burning, typically located retrosternally but possibly radiating to the neck, jaw, left arm, or back. Accompanying symptoms frequently include profuse sweating, nausea, vomiting, dyspnea, and a sense of impending doom. In some individuals- particularly the elderly, women, and those with diabetes - symptoms may be atypical or muted, manifesting as unexplained fatigue, indigestion, or shortness of breath without significant chest pain.

Picture 4. *Myocardial Infarction (MI)*

Electrocardiographic changes are central to diagnosing MI. In ST-elevation myocardial infarction, persistent ST-segment elevation appears in leads

corresponding to the infarcted territory, often accompanied by reciprocal ST depression in opposing leads. Pathological Q waves may develop within hours to days, reflecting transmural necrosis. In non-ST-elevation myocardial infarction, ST depression or T-wave inversion is seen without persistent ST elevation; biomarkers confirm necrosis. Cardiac troponins- now the gold standard- rise within three to six hours, peak at around twenty-four hours, and remain elevated for up to two weeks. Creatine kinase-MB isoenzyme provides additional corroboration but lacks the sensitivity and specificity of troponin.

Beyond ECG and biomarkers, imaging plays an important role. Echocardiography reveals regional wall motion abnormalities, which correspond to areas of infarction and can help distinguish MI from other causes of chest pain. Cardiac magnetic resonance imaging offers detailed tissue characterization, identifying edema, necrosis, and scar formation. Coronary angiography confirms the location and extent of occlusion, guides revascularization, and assesses the need for stenting or bypass surgery.

Immediate management focuses on restoring perfusion to minimize infarct size and preserve left ventricular function. Reperfusion is achieved either pharmacologically- using fibrinolytic agents to dissolve the thrombus- or mechanically via primary percutaneous coronary intervention (PCI). When performed promptly, PCI offers superior outcomes, reducing mortality and the risk of complications. Adjunctive therapies include dual antiplatelet therapy (aspirin plus a $P2Y_{12}$ inhibitor), anticoagulation (e.g., heparin), and high-intensity statins to stabilize plaques and reduce inflammation. Beta-blockers decrease myocardial oxygen demand by slowing heart rate and reducing contractility, while ACE inhibitors or angiotensin receptor blockers mitigate remodeling and heart failure risk.

Complications span electrical, mechanical, and inflammatory domains. Ventricular arrhythmias- such as ventricular tachycardia and fibrillation- occur most commonly in the early hours and often cause sudden cardiac death. Heart

block may result from ischemia of the conduction system, particularly in inferior infarctions. Mechanical complications, though less frequent in the era of rapid reperfusion, remain serious: papillary muscle rupture leads to acute severe mitral regurgitation and pulmonary edema; ventricular septal rupture causes a left-to-right shunt with hemodynamic collapse; free wall rupture precipitates tamponade. Myocardial inflammation can give rise to pericarditis, presenting days after the infarction.

Long-term care focuses on preventing recurrent events and managing heart failure. Cardiac rehabilitation- including supervised exercise, dietary counseling, and smoking cessation- improves functional capacity and quality of life. Optimizing medical therapy with ACE inhibitors, beta-blockers, statins, and antiplatelet agents reduces the risk of reinfarction and death. Patients undergo periodic assessment of left ventricular function, often with echocardiography, to guide decisions about implantable cardioverter-defibrillators in those with severely reduced ejection fraction.

Myocardial infarction represents the most severe manifestation of ischemic heart disease, marked by abrupt coronary occlusion, irreversible myocardial necrosis, and a spectrum of acute and chronic complications. Rapid recognition, prompt reperfusion, and comprehensive secondary prevention are essential to limit myocardial damage, avert life-threatening events, and improve long-term outcomes.

Asymptomatic (Silent) Ischemia

In many patients- particularly those with diabetes, the elderly, or those on β-blockers- islands of myocardial oxygen deprivation occur without any chest pain or discomfort. These episodes are often undetected unless specifically sought with continuous ECG monitoring, stress imaging, or wearable cardiac monitors. On ECG, one might see transient ST-segment depressions or T-wave inversions even as the patient remains symptom-free.

Mechanistically, silent ischemia arises when modest reductions in coronary flow fail to trigger pain fibers or when neuropathic changes blunt pain perception. Repeated brief ischemic insults may even induce a form of "preconditioning," diminishing nociceptor sensitivity over time. Despite the absence of pain, silent ischemia carries a risk of myocardial infarction and adverse cardiovascular events comparable to symptomatic ischemia. Its detection should prompt optimization of anti-ischemic therapy- such as β-blockers, nitrates, and calcium channel blockers- and rigorous risk-factor control, including tight glycemic management, blood pressure regulation, statin therapy, and smoking cessation. In cases where extensive silent ischemia is documented, referral for coronary angiography and consideration of revascularization may improve outcomes.

Initial versus advanced disease stages

In the earliest stage of ischemic heart disease, patients typically experience chest discomfort only during significant increases in exertion or emotional stress. At this point, atherosclerotic plaques have narrowed the coronary lumen enough that small resistance vessels cannot dilate sufficiently to meet spikes in myocardial oxygen demand. Anginal episodes are predictable: they occur with a specific level of activity-such as climbing stairs or hurrying to catch a bus-and resolve promptly with rest or nitroglycerin. Electrocardiograms may be normal at rest, and left ventricular function is usually preserved. Collateral vessels may already be developing, providing some protection against total occlusion.

As disease progresses, the threshold for ischemia falls. Angina begins to appear during everyday activities-walking on level ground, dressing, or minor emotional upset-and may even awaken the patient from sleep. Episodes lengthen and become more frequent, and relief with rest or medication takes longer. Transient ischemia can evolve into unstable angina, where chest pain occurs unpredictably and carries a higher risk of myocardial infarction. Silent ischemia may emerge alongside pain episodes, as repeated brief insults desensitize cardiac nociceptors.

In advanced stages, fixed obstructions may precipitate myocardial infarction, either through plaque rupture and thrombosis or via critical stenosis combined with increased demand. Infarction causes irreversible loss of contractile tissue, leading to impaired systolic function, ventricular remodeling, and dilation. Patients often develop heart failure symptoms-exertional dyspnea, orthopnea, fatigue-and are at risk for life-threatening arrhythmias. Mechanical complications, such as papillary muscle rupture or septal defects, can further destabilize the clinical picture. At this point, management shifts from purely medical therapy toward revascularization, device implantation, and intensive heart failure care to preserve remaining myocardium and prevent further deterioration.

Common complications of Ischemic Heart Disease

Ischemic heart disease often leads to a cascade of downstream problems once myocardial blood flow is compromised. One of the earliest and most frequent sequelae is the development of electrical instability within the heart. As ischemic or infarcted tissue alters the normal conduction pathways, patients become prone to arrhythmias-ranging from benign premature beats to life-threatening ventricular tachycardia or fibrillation. These ventricular arrhythmias are the most common cause of sudden cardiac death in IHD, while atrial fibrillation may arise from atrial stretch due to elevated filling pressures or scarring.

Progressive loss of viable myocardium also impairs the heart's pumping ability. Left ventricular dysfunction initially manifests as exertional breathlessness and fatigue; over time, chronic systolic and diastolic dysfunction culminate in overt heart failure. Patients describe increasing dyspnea on minimal exertion or when lying flat, and physical findings may include pulmonary crackles, jugular venous distension, and peripheral edema. Neurohormonal activation (renin-angiotensin-aldosterone system, sympathetic nervous system) perpetuates remodeling, leading to chamber dilation, wall thinning, and worsening function.

Although less common today with early reperfusion, mechanical complications of myocardial infarction still occur and carry high mortality. Rupture

of the interventricular septum produces a harsh holosystolic murmur with acute hemodynamic collapse; papillary muscle rupture leads to severe mitral regurgitation, acute pulmonary edema, and hypotension; free-wall rupture results in hemopericardium and tamponade, often causing sudden death. Ventricular aneurysm formation during the healing phase may lead to persistent heart failure, thrombus formation, or recurrent arrhythmias. Inflammatory responses following infarction can give rise to pericarditis, which typically presents days after the event with pleuritic chest pain relieved by leaning forward and a friction rub on auscultation. Dressler's syndrome, an autoimmune pericarditis occurring weeks later, adds fever, leukocytosis, and pericardial effusion to the picture.

Finally, chronic ischemia promotes progressive atherosclerosis and endothelial dysfunction in other vascular beds, increasing the risk of stroke, peripheral arterial disease, and renal impairment. Thus, ischemic heart disease rarely exists in isolation; its complications span electrical, mechanical, inflammatory, and systemic vascular domains, underscoring the need for comprehensive surveillance and multi-modal management.

2.2. Diagnostic approaches in Ischemic Heart Disease

Accurate diagnosis of ischemic heart disease (IHD) relies on an integrated strategy that combines modern imaging and functional studies with thorough clinical assessment and targeted laboratory testing. Early detection of myocardial ischemia can prevent progression to infarction, while recognition of advanced disease guides appropriate intervention. Below, we explore contemporary diagnostic tools-electrocardiography, echocardiography, and computed tomography-describe methodologies suited to both initial and late-stage IHD, and review how clinical presentation and biomarkers contribute to establishing the diagnosis.

Electrocardiography (ECG) remains the cornerstone of IHD evaluation. A standard 12-lead ECG performed at rest may demonstrate signs of prior infarction

(pathological Q-waves), ongoing ischemia (ST-segment depression or T-wave inversion), or acute injury (ST-segment elevation). However, many patients-especially in early or microvascular disease-have normal resting tracings. Exercise stress testing augments sensitivity by provoking ischemia beneath exertional conditions. During a graded treadmill or bicycle protocol, continuous ECG monitoring identifies dynamic ST-segment shifts, heart rate-blood pressure responses, and arrhythmias. The addition of imaging modalities-stress echocardiography assessing regional wall motion abnormalities, or nuclear perfusion scanning highlighting reversible defects-further refines diagnostic accuracy and provides prognostic information about ischemic burden. Echocardiography offers real-time visualization of cardiac structure and function without ionizing radiation. Transthoracic echo can detect regional wall motion abnormalities at rest, suggestive of prior infarction or hibernating myocardium. In suspected acute ischemia, dobutamine stress echocardiography reveals inducible dysfunction: segments that contract normally at baseline but become hypokinetic or akinetic under pharmacologic stress indicate flow-limiting coronary lesions. Doppler evaluation quantifies valve function, filling pressures, and pulmonary pressures, essential in differentiating ischemic dyspnea from primary valvular or pulmonary pathology.

Picture 5. *12-Channel Electrocardiograph*

Coronary computed tomography angiography (CCTA) has emerged as a noninvasive method to visualize coronary anatomy with high spatial resolution.

Modern multi-detector CT scanners enable rapid acquisition of volumetric data, reconstructing three-dimensional images of coronary lumens and vessel walls. Plaque characterization-calcium scoring, lipid-rich versus fibrous composition-helps stratify risk, even

Picture 6. *Computed tomography (CT)*

before critical stenoses develop. In low-to intermediate-risk patients presenting with chest pain, CCTA can effectively rule out significant coronary artery disease, reducing unnecessary invasive angiography. However, heart rate control and contrast considerations limit its use in certain populations.

Detecting early and advanced disease

Initial stages of IHD often escape detection by routine tests due to preserved resting perfusion or collateral circulation. Functional testing under stress conditions-exercise ECG or stress imaging-remains the principal method for unmasking demand ischemia. In patients unable to exercise, pharmacologic stress agents (adenosine, dipyridamole, or dobutamine) simulate increased myocardial demand or induce coronary vasodilation, thereby identifying flow-limiting lesions. Ambulatory ECG (Holter) monitoring detects silent ischemia by capturing transient ST-segment depressions during normal activities, offering insight into subclinical disease.

In advanced IHD, diagnostic focus shifts toward defining the extent of myocardial damage and guiding revascularization. Invasive coronary angiography continues as the gold standard, directly visualizing luminal narrowing and permitting percutaneous or surgical intervention. Fractional flow reserve (FFR)

measurements obtained during angiography quantify the physiologic significance of intermediate lesions, refining decision-making for stenting versus medical therapy. Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) provide intraluminal imaging of plaque morphology, cap thickness, and vessel remodeling, offering detailed insights into plaque vulnerability and mechanisms of acute coronary syndromes.

Cardiac magnetic resonance imaging (MRI) serves as an adjunct in complex cases. Late gadolinium enhancement sequences distinguish infarcted from viable myocardium, aiding in risk stratification for arrhythmic complications and guiding decisions on revascularization or device implantation. Stress perfusion MRI parallels nuclear imaging in detecting ischemia without radiation exposure, although limited availability and cost restrict routine use.

Clinical evaluation and laboratory indicators

A comprehensive clinical history remains fundamental. Key elements include the character, timing, and triggers of chest discomfort; alleviating factors; and associated symptoms such as dyspnea, diaphoresis, nausea, or syncope. Physical examination assesses hemodynamics, reveals signs of heart failure (jugular venous distension, pulmonary crackles, peripheral edema), and identifies new murmurs suggestive of mechanical complications.

Laboratory testing complements imaging and clinical data. Cardiac troponins I and T have revolutionized the diagnosis of myocardial injury, rising within three to six hours of onset, peaking at 12-24 hours, and remaining elevated for up to two weeks. Even minor troponin elevations carry prognostic significance in unstable angina and non-ST-elevation acute coronary syndromes. Creatine kinase-MB (CK-MB) remains useful for detecting reinfarction, given its shorter half-life. Additional biomarkers-such as B-type natriuretic peptide (BNP) or N-terminal proBNP-reflect myocardial strain and correlate with heart failure severity.

Routine laboratory evaluation also screens for modifiable risk factors. Lipid profiling (total cholesterol, LDL, HDL, and triglycerides) guides lipid-lowering therapy, while glycemic assessment (fasting glucose, HbA1c) identifies diabetic patients who often present with atypical or silent ischemia. High-sensitivity C-reactive protein (hs-CRP) serves as a marker of systemic inflammation and atherosclerotic activity, predicting cardiovascular events even in individuals with normal cholesterol levels. Renal function tests inform medication dosing and risk stratification, as chronic kidney disease amplifies cardiovascular risk.

Integration and risk stratification

No single test definitively rules in or out IHD in all patients. Instead, clinicians integrate data from ECG, imaging studies, functional tests, clinical evaluation, and laboratory biomarkers to arrive at a diagnosis and estimate risk. Pretest probability-derived from age, sex, and symptom profile-guides test selection: low-risk patients may forgo further evaluation after a negative ECG and cardiac biomarker panel, whereas high-risk individuals proceed directly to angiography. Intermediate-risk patients benefit most from noninvasive stress testing or CCTA.

Risk scores, such as the TIMI (Thrombolysis In Myocardial Infarction) or GRACE (Global Registry of Acute Coronary Events), combine clinical and laboratory variables to predict outcomes in acute settings, tailoring the intensity of monitoring and intervention. Long-term prognostication uses metrics like left ventricular ejection fraction, extent of ischemia on stress imaging, and infarct size by MRI to guide therapy and follow-up.

Effective diagnosis of ischemic heart disease demands a multimodal approach. Electrocardiography, echocardiography, and computed tomography provide structural and functional insights; stress testing and invasive methods distinguish early from late disease; and clinical assessment combined with laboratory biomarkers rounds out the diagnostic picture. By tailoring diagnostic pathways to individual risk profiles and resource availability, clinicians can

identify IHD promptly, target appropriate therapies, and ultimately improve patient outcomes.

2.3. Disease progression and complications in IHD

Ischemic heart disease (IHD) is not a static entity but a dynamic process that evolves over years or decades, shaped by the interplay between coronary anatomy, myocardial adaptation, and systemic factors. Understanding its clinical trajectory and identifying the determinants of progression are essential for mitigating adverse outcomes and guiding therapeutic interventions.

In its earliest manifestations, IHD typically presents with predictable exertional angina, reflecting transient imbalances between myocardial oxygen demand and supply. Over time, repeated episodes of ischemia-whether symptomatic or silent-inflict cumulative injury on cardiomyocytes, eroding contractile reserve and impairing ventricular function. This gradual decline often remains clinically occult until compensatory mechanisms fail, at which point patients may experience more frequent angina, resting discomfort, or frank heart failure.

The transition from stable to unstable disease marks a pivotal prognostic threshold. Stable IHD, managed with medications and lifestyle changes, carries an annual mortality risk of approximately 1-2 percent. However, once plaque destabilization occurs-manifesting as progressive or rest angina-the risk of myocardial infarction and sudden cardiac death rises sharply, with short-term mortality rates exceeding 10 percent in some cohorts. The occurrence of a myocardial infarction further accelerates disease progression by inducing permanent loss of contractile tissue, promoting adverse ventricular remodeling, and predisposing to mechanical and electrical complications.

Long-term prognosis in IHD hinges on multiple factors: the extent of coronary obstruction, left ventricular ejection fraction, presence of comorbidities (such as diabetes or chronic kidney disease), and patient adherence to therapy.

Noninvasive imaging and invasive measures-such as perfusion scans, stress echocardiography, and fractional flow reserve-help stratify patients into low-, intermediate-, or high-risk categories, informing decisions about revascularization versus medical management. Ultimately, the clinical course is modifiable; aggressive control of risk factors and timely revascularization can stabilize or even reverse functional decline.

Several interrelated factors influence the pace and severity of IHD progression:

1. **Plaque biology and instability**: Vulnerable atherosclerotic plaques-characterized by large lipid cores, thin fibrous caps, and abundant inflammatory cells-are prone to rupture. The frequency of subclinical plaque disruptions predicts the likelihood of overt acute coronary syndromes. High levels of systemic inflammation (measured by biomarkers such as high-sensitivity C-reactive protein) correlate with plaque vulnerability and faster disease progression.

2. **Metabolic comorbidities**: Diabetes mellitus exerts a profound accelerating effect on atherosclerosis via chronic hyperglycemia, increased oxidative stress, and endothelial dysfunction. Diabetic patients often develop diffuse, calcified coronary lesions that are less amenable to revascularization and more likely to produce silent ischemia, complicating early detection.

3. **Hypertension and Hemodynamic stress**: Elevated blood pressure increases shear stress on arterial walls, promoting endothelial injury and plaque formation. Poorly controlled hypertension not only contributes to plaque development but also augments myocardial oxygen demand, hastening the onset of ischemia.

4. **Lipid profiles**: Persistent elevations in low-density lipoprotein cholesterol drive plaque growth, while low levels of high-density lipoprotein cholesterol diminish protective reverse-cholesterol transport. The ratio of apolipoprotein

B to apolipoprotein A1 has emerged as a robust predictor of cardiovascular risk, reflecting the balance of atherogenic and anti-atherogenic particles.

5. **Lifestyle factors**: Tobacco use remains among the most potent modifiable determinants of poor prognosis in IHD. Smoking induces vasoconstriction, enhances thrombogenicity, and accelerates oxidative injury within plaques. Sedentary behavior and unhealthy diets (high in saturated fats and refined carbohydrates) further compound risk by worsening lipid profiles, insulin sensitivity, and systemic inflammation.

6. **Neurohormonal activation**: Chronic ischemia triggers sympathetic nervous system and renin-angiotensin-aldosterone system activation, promoting vasoconstriction, sodium retention, and ventricular remodeling. Persistent neurohormonal stimulation leads to fibrosis, arrhythmia susceptibility, and deterioration of systolic and diastolic function.

By addressing these determinants-through statins, antihypertensives, glycemic control, smoking cessation, and exercise-clinicians can alter the natural history of IHD, slowing plaque progression and preserving myocardial performance.

The complications of IHD encompass electrical, mechanical, and systemic sequelae, each demanding targeted preventative and therapeutic strategies.

- **Arrhythmias**: Myocardial ischemia and infarction disrupt the uniform electrical conduction of the heart, creating areas of slowed conduction and reentry circuits. Ventricular arrhythmias (ventricular tachycardia or fibrillation) are the leading cause of sudden cardiac death. Preventive measures include beta-blockers-which reduce sympathetic stimulation-and mineralocorticoid receptor antagonists in post-infarction patients, which lower arrhythmic risk. In patients with severely reduced ejection fraction (<35 percent), implantable cardioverter-defibrillators provide lifesaving protection against lethal arrhythmias.

- **Heart failure**: Chronic ischemia and infarct-related loss of myocardium undermine systolic function, while diastolic stiffness from fibrosis impairs filling. The neurohormonal response to reduced cardiac output exacerbates remodeling and volume overload. Guideline-directed medical therapy-comprising ACE inhibitors (or angiotensin receptor blockers), beta-blockers, and mineralocorticoid antagonists-attenuates remodeling, reduces hospitalizations, and improves survival. Emerging agents, such as angiotensin receptor-neprilysin inhibitors, offer additional benefit by enhancing natriuretic peptide signaling.

- **Mechanical complications**: Though rare in the contemporary era of rapid reperfusion, papillary muscle rupture, septal defects, and free-wall rupture can occur within days of large transmural infarctions. Early identification via vigilant clinical monitoring (new murmurs, acute pulmonary edema, or hypotension) and prompt surgical intervention are critical to survival. Prophylactic strategies-namely, reduction of infarct size through timely reperfusion-remain the cornerstone of prevention.

- **Thromboembolic events**: Left ventricular thrombus formation over akinetic or dyskinetic segments can lead to systemic embolism. Prophylactic anticoagulation in patients with extensive anterior infarctions or low ejection fraction reduces stroke risk. Dual antiplatelet therapy following acute coronary syndromes mitigates recurrent thrombosis on disrupted plaques or stents.

- **Pericarditis and Dressler's syndrome**: Inflammation of the pericardium may follow transmural infarction, presenting with pleuritic chest pain and pericardial friction rub. Nonsteroidal anti-inflammatory drugs provide symptomatic relief, while colchicine (in selected cases) reduces recurrence. Dressler's syndrome, an autoimmune pericarditis weeks post-MI, likewise responds to anti-inflammatory agents under careful hemodynamic monitoring.

Picture 7. Dressler's syndrome

In all patients, comprehensive secondary prevention is paramount. High-intensity statin therapy stabilizes plaques, lowers low-density lipoprotein cholesterol, and exerts anti-inflammatory effects. Lifestyle interventions-smoking cessation, aerobic exercise, Mediterranean-style diet, and weight management-synergize with pharmacotherapy to reduce recurrent events. Cardiac rehabilitation programs, integrating supervised exercise, education, and psychosocial support, enhance functional capacity and long-term adherence.

Ischemic heart disease unfolds along a continuum from silent atherosclerosis to overt heart failure and sudden death. Early-stage disease offers a window of opportunity for intervention, whereas advanced complications demand multifaceted management strategies. By elucidating the factors that drive progression-plaque instability, comorbid metabolic disorders, hemodynamic stress, and lifestyle influences-clinicians can implement targeted therapies that arrest disease progression, prevent complications, and improve survival. A proactive approach to surveillance, risk-factor control, and individualized treatment plans remains the cornerstone of optimal care in ischemic heart disease.

Chapter III. TREATMENT APPROACHES FOR ISCHEMIC HEART DISEASE

3.1. Pharmacotherapeutic approaches

Pharmacotherapy forms the cornerstone of modern management for ischemic heart disease, aiming both to alleviate symptoms and to modify the natural history of atherosclerosis. Four principal classes of medications-β-adrenergic blockers, statins, angiotensin-converting enzyme (ACE) inhibitors, and antithrombotic agents-have demonstrated robust benefits in large-scale clinical trials. By targeting distinct yet complementary pathophysiological pathways, these drugs reduce myocardial oxygen demand, stabilize atherosclerotic plaques, inhibit vasoconstrictive and fibrotic signaling, and prevent thrombus formation. Their judicious use according to evidence-based guidelines yields substantial reductions in mortality, recurrent infarction, and heart failure progression.

β-Adrenergic Blockers

β-Blockers decrease myocardial oxygen consumption by blunting sympathetic stimulation. They slow heart rate, reduce contractility, and lower systolic blood pressure-thereby shifting the oxygen supply-demand balance in favor of myocardial perfusion. Landmark trials such as the Norwegian Timolol Trial and subsequent post-MI studies established that early administration of β-blockers after myocardial infarction reduces arrhythmic deaths, reinfarction rates, and overall mortality. In stable angina, β-blockers increase exercise tolerance and delay onset of ischemia during stress testing. Current guidelines recommend initiation of a selective β_1-blocker (e.g., metoprolol or bisoprolol) in all patients post-acute coronary syndrome unless contraindicated.

Beyond symptomatic relief, β-blockers favorably influence key risk factors. By attenuating sympathetic overactivity, they mitigate stress-induced hypertension and reduce left ventricular remodeling. Long-term use has been associated with decreased progression to heart failure in post-MI cohorts. Adverse effects-such as fatigue, bradycardia, and potential masking of hypoglycemia-are generally

manageable by careful dose titration. In patients with reactive airway disease, use of cardioselective agents or alternative therapies should be considered.

Statins

HMG-CoA reductase inhibitors, or statins, revolutionized the prevention of atherosclerotic cardiovascular disease by potently lowering low-density lipoprotein cholesterol (LDL-C). Large outcome trials-4S, WOSCOPS, and subsequent meta-analyses-demonstrated that intensive statin therapy reduces major adverse cardiac events (MACE) by approximately 25-30% and all-cause mortality by 15-20% over five years. Statins also exert pleiotropic effects: they improve endothelial function, stabilize vulnerable plaques by reducing lipid core and inflammation, and decrease oxidative stress.

Guideline recommendations call for high-intensity statin therapy (e.g., atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily) for all patients with established ischemic heart disease, regardless of baseline LDL-C levels. In addition to LDL-C reduction, statins modestly lower triglycerides and raise high-density lipoprotein cholesterol (HDL-C). Their anti-inflammatory action-evidenced by reductions in C-reactive protein-has been linked to better outcomes in patients with elevated inflammatory markers. Long-term adherence to statin therapy halts progression of coronary atheroma on intravascular ultrasound studies and further diminishes recurrent events. Common side effects, including myalgias and mild transaminase elevations, generally resolve with dose adjustment or switching agents.

Angiotensin-Converting Enzyme inhibitors

ACE inhibitors block conversion of angiotensin I to angiotensin II, thereby reducing vasoconstriction, aldosterone-mediated volume expansion, and maladaptive remodeling. The landmark SAVE and AIRE trials demonstrated that early initiation of captopril or ramipril following myocardial infarction reduces mortality by approximately 20%, limits left ventricular dilatation, and lowers

incidence of heart failure. In patients with asymptomatic left ventricular dysfunction (ejection fraction <40%) or clinical heart failure, ACE inhibitors confer similar survival benefits.

Picture 8. ACE Inhibitors Save Lives.

Current practice guidelines advocate ACE inhibitors-or angiotensin receptor blockers when ACE inhibitors are not tolerated-for virtually all patients with ischemic heart disease, especially those with hypertension, diabetes, or left ventricular systolic dysfunction. By lowering afterload and mitigating adverse remodeling, these agents prolong event-free survival. They also improve endothelial function and reduce arterial stiffness. Adverse effects include cough (due to bradykinin accumulation), hyperkalemia, and, rarely, angioedema; monitoring of renal function and electrolytes is essential during therapy initiation and uptitration.

Antithrombotic therapy

Thrombosis superimposed on ruptured or eroded atherosclerotic plaques underlies most acute coronary syndromes. Low-dose aspirin irreversibly inhibits platelet cyclooxygenase-1, reducing thromboxane A_2-mediated platelet aggregation. The ISIS-2 trial firmly established aspirin's life-saving benefit post-

MI, with an approximate 25% reduction in vascular mortality. Dual antiplatelet therapy-combining aspirin with a P2Y$_{12}$ receptor inhibitor such as clopidogrel, prasugrel, or ticagrelor-further decreases stent thrombosis and recurrent ischemic events in patients undergoing percutaneous coronary intervention. In addition to antiplatelet agents, anticoagulants (e.g., unfractionated heparin, low-molecular-weight heparin) are indicated in the acute management of unstable angina/non−ST-elevation MI to inhibit thrombin generation and propagation. Novel oral anticoagulants (e.g., rivaroxaban at low doses) have shown promise in secondary prevention when added to antiplatelet therapy, albeit with an increased bleeding risk. The choice and duration of antithrombotic regimens must balance ischemic protection against hemorrhagic complications, guided by validated risk scores (e.g., DAPT score).

Drug efficacy and clinical indications

β-blockers are indicated in all patients post-myocardial infarction and in those with stable angina who tolerate them, particularly if hypertension, tachyarrhythmias, or left ventricular dysfunction co-exist. Statins are mandated for any patient with documented atherosclerotic cardiovascular disease, with dose intensity adjusted to achieve LDL-C targets (typically <70 mg/dL). ACE inhibitors/ARBs are essential in patients with reduced ejection fraction, hypertension, diabetes, or chronic kidney disease. Aspirin is prescribed indefinitely for all patients with IHD, while P2Y$_{12}$ inhibitors are continued for at least 12 months following drug-eluting stent placement or acute coronary syndrome.

These medications demonstrate synergistic benefits. For instance, combined use of β-blockers and ACE inhibitors post-MI reduces mortality more than either agent alone. Statins and ACE inhibitors jointly enhance endothelial repair, while antiplatelet agents minimize thrombotic risk across all stages of disease. Adherence to combination therapy per guidelines can lower five-year mortality by over 50% compared with suboptimal regimens.

Impact on risk factors and long-term outcomes

Pharmacotherapy not only treats acute episodes but also modifies underlying risk factors. β-Blockers improve blood pressure control and attenuate stress responses; statins markedly lower atherogenic lipid levels; ACE inhibitors reduce hypertension and protect renal function in diabetics; antithrombotics forestall acute thrombosis. Over the long term, these interventions decelerate atheroma progression, promote plaque stabilization, and preserve myocardial viability. Observational cohorts and randomized trials confirm that patients consistently receiving evidence-based pharmacotherapy have lower rates of reinfarction, hospitalizations for heart failure, and sudden cardiac death.

Side effects and interactions require vigilance but seldom outweigh benefits. Frequent monitoring-clinical and laboratory-ensures early detection of adverse reactions (e.g., bradycardia, myopathy, hyperkalemia, or bleeding). Patient education and multidisciplinary support enhance adherence, further improving outcomes.

Optimal pharmacotherapeutic management of ischemic heart disease hinges on four foundational drug classes. β-Blockers, statins, ACE inhibitors, and antithrombotic agents each address key elements of IHD pathophysiology, from reducing myocardial workload to preventing thrombosis and stabilizing plaque. Their combined, guideline-driven use yields dramatic reductions in mortality, recurrent ischemia, and heart failure. By tailoring therapy to individual risk profiles and monitoring for efficacy and safety, clinicians can deliver durable benefit and markedly improve the long-term prognosis of patients with ischemic heart disease.

3.2. Invasive treatment modalities

Invasive interventions play a pivotal role in the management of ischemic heart disease (IHD) when medical therapy alone is insufficient to relieve symptoms or mitigate risk. Two principal invasive strategies-percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG)-have distinct

mechanisms, technical considerations, and indications. Understanding their evolution, comparative efficacy, and appropriate application enables clinicians to tailor revascularization to individual patient anatomy, comorbidities, and long-term prognosis.

PCI, originally introduced as balloon angioplasty in the late 1970s, revolutionized the field by offering a catheter-based means of dilating stenotic coronary arteries without open surgery. Balloon angioplasty, however, was limited by vessel recoil and high rates of restenosis due to elastic recoil and neointimal hyperplasia. The advent of bare-metal stents in the mid-1980s addressed these limitations by providing a scaffold to maintain luminal patency, reducing acute vessel closure and early restenosis. Further refinement led to drug-eluting stents (DES) in the early 2000s, which released antiproliferative agents-such as sirolimus or paclitaxel-from polymer coatings, dramatically lowering neointimal proliferation and late lumen loss.

Modern PCI involves vascular access (commonly via the radial or femoral artery), coronary catheterization under fluoroscopic guidance, lesion crossing with guidewires, balloon pre-dilatation (if needed), stent deployment, and post-dilatation to ensure optimal stent apposition. Intracoronary imaging-using intravascular ultrasound (IVUS) or optical coherence tomography (OCT)-can identify lesion morphology, calcification, and stent expansion, guiding procedural optimization and reducing complications. Physiologic assessment with fractional flow reserve (FFR) helps determine the hemodynamic significance of intermediate lesions, avoiding unnecessary stenting and improving outcomes.

Large randomized trials have compared DES-based PCI with medical therapy and with CABG in various clinical settings. In stable multivessel disease, the COURAGE trial showed no difference in death or myocardial infarction between PCI plus optimal medical therapy versus medical therapy alone over five years, though PCI improved anginal symptoms. The SYNTAX trial compared PCI with first-generation DES versus CABG in complex multivessel and left main

disease, demonstrating higher rates of repeat revascularization with PCI, particularly in patients with high anatomical complexity (SYNTAX score >22). Subsequent iterations-SPIRIT, ENDEAVOR, and others-evaluated newer DES platforms with thinner struts and biocompatible polymers, further reducing restenosis and stent thrombosis rates to below 5% at one year.

Clinical indications for PCI include acute ST-elevation myocardial infarction, where primary PCI within 90 minutes of first medical contact is the preferred reperfusion strategy, yielding superior survival compared with fibrinolysis. In non-ST-elevation acute coronary syndromes (NSTEMI and unstable angina), an early invasive approach within 24 hours reduces recurrent ischemia and rehospitalization. For stable angina, PCI is indicated in patients with significant proximal lesions, large ischemic territory on noninvasive testing, or refractory symptoms despite optimal medical therapy. Lesion characteristics-such as long, calcified, or bifurcation stenoses-may increase procedural complexity, but dedicated techniques (rotational atherectomy, bifurcation stenting, chronic total occlusion approaches) enable successful revascularization in over 90% of cases in experienced centers.

Complications of PCI include vessel perforation, coronary dissection, acute stent thrombosis, contrast-induced nephropathy, and vascular access site bleeding. Dual antiplatelet therapy (aspirin plus a $P2Y_{12}$ inhibitor) for at least six to twelve months post-DES is crucial to prevent stent thrombosis, with the choice and duration tailored to bleeding risk and clinical scenario. Radial access has reduced major bleeding and improved patient comfort compared with femoral access, and is now the preferred approach in many centers.

Coronary Artery Bypass Grafting

CABG, first performed in the 1960s, remains the gold standard for revascularization in patients with left main coronary disease, complex multivessel disease-particularly in diabetics-and impaired left ventricular function. The procedure involves harvesting conduits (internal mammary arteries, saphenous

vein grafts, or radial arteries) and creating surgical anastomoses between these grafts and the coronary arteries distal to the obstructive lesions, thereby bypassing flow-limiting stenoses.

Picture 9. Coronary Artery Bypass Graft

The left internal mammary artery (LIMA) to left anterior descending artery (LAD) graft has demonstrated excellent long-term patency (>90% at ten years) and survival benefit, attributed to its resistance to atherosclerosis. Saphenous vein grafts have lower long-term patency-approximately 50% remain patent at ten years-owing to intimal hyperplasia and accelerated atherosclerosis. Use of bilateral internal mammary arteries or radial artery grafts can improve durability but may increase surgical complexity and risk of sternal wound complications.

Multiple randomized trials and meta-analyses have established the superiority of CABG over medical therapy or PCI in selected high-risk populations. The FREEDOM trial compared CABG with PCI (using DES) in diabetic patients with multivessel disease, showing significantly lower rates of death and myocardial infarction with CABG at five years, albeit with higher stroke risk. The SYNTAX trial demonstrated that in patients with high anatomical complexity, CABG resulted in lower major adverse cardiac and cerebrovascular events (MACCE) compared with PCI over three years. CABG also benefits

patients with left ventricular dysfunction, as evidenced by the STICH trial, which showed improved survival and reduced heart failure hospitalizations with surgical revascularization plus medical therapy versus medical therapy alone in patients with ejection fraction ≤35%.

CABG is typically performed via median sternotomy under cardiopulmonary bypass (on-pump), although off-pump techniques (beating-heart surgery) have gained popularity to reduce inflammatory response, cerebral microembolism, and bleeding in selected patients. Hybrid operating rooms now enable combined CABG and PCI in a single session ("hybrid revascularization"), leveraging the durability of LIMA-LAD grafts and targeted PCI for non-LAD lesions.

Postoperative complications include graft occlusion, myocardial infarction, arrhythmias (particularly atrial fibrillation), stroke, infection, and cognitive dysfunction. Advances in myocardial protection, anesthetic management, and perioperative care have reduced mortality to below 2% in low-risk patients, though higher in the elderly and those with comorbidities. Long-term secondary prevention-optimal medical therapy, lifestyle modification, and cardiac rehabilitation-remains essential to maintain graft patency and overall cardiovascular health.

Deciding between PCI and CABG requires a multidisciplinary heart team approach, integrating anatomical, clinical, and patient-centered factors. The American College of Cardiology/American Heart Association and European Society of Cardiology guidelines recommend CABG for left main stenosis >50%, multivessel disease with diabetes, or three-vessel disease with impaired left ventricular function. PCI is preferred in single- or double-vessel disease without high-risk features, or when surgical risk is prohibitive. The SYNTAX score quantifies anatomical complexity-scores ≤22 favor PCI, whereas >32 strongly favor CABG. FFR and instantaneous wave-free ratio (iFR) guide physiologic lesion assessment, optimizing PCI decision-making and reducing unnecessary revascularization.

In acute coronary syndromes, primary PCI within guideline-recommended timeframes dramatically reduces mortality and preserves myocardial function. In patients presenting with cardiogenic shock, emergent PCI or CABG as part of revascularization strategy improves survival. For chronic stable angina refractory to medical therapy but without high-risk anatomy, PCI provides symptom relief and quality-of-life improvement, though does not alter long-term survival compared with medical therapy alone.

In surgical candidates, off-pump CABG may benefit those with heavily calcified aortas or coagulopathy, while on-pump remains standard for most. Conduit selection and graft configuration-single versus multiple arterial grafts-impact long-term outcomes, with arterial conduits preferred in younger patients to maximize durability. Hybrid revascularization offers tailored solutions for complex anatomies, combining surgical and percutaneous expertise. Ultimately, invasive treatment modalities for IHD complement rather than replace pharmacotherapy. Optimal outcomes derive from an integrated strategy: aggressive medical management of risk factors, judicious selection of revascularization based on current guidelines and patient preferences, meticulous procedural technique, and comprehensive postprocedure care. In this era of personalized medicine, the heart team model ensures that each patient receives the most appropriate revascularization strategy, balancing procedural risk, expected benefit, and long-term prognosis.

3.3. Prevention and patient follow-up IHD

Effective long-term management of ischemic heart disease (IHD) demands a proactive blend of prevention strategies and personalized monitoring. Beyond acute treatment and revascularization, a comprehensive approach focuses on minimizing risk factors, optimizing pharmacotherapy, engaging patients in lifestyle modifications, and tailoring care to individual needs. As new therapies emerge,

integrating evidence-based preventive measures and structured follow-up protocols becomes essential to reduce recurrent events and enhance quality of life.

Pharmacological and Non-Pharmacological Prevention

Preventing IHD begins with mitigating the underlying drivers of atherosclerosis and thrombosis. Pharmacological interventions target lipid metabolism, platelet aggregation, blood pressure, and metabolic conditions, while non-pharmacological methods harness the power of diet, exercise, and behavioral change.

High-intensity statin therapy remains the cornerstone of pharmacological prevention. By inhibiting HMG-CoA reductase, statins achieve substantial reductions in low-density lipoprotein cholesterol (LDL-C), slowing plaque progression and stabilizing vulnerable lesions. Landmark trials have demonstrated that intensive statin regimens lower major adverse cardiovascular events by approximately 30 percent, with benefits observed even in patients without markedly elevated baseline LDL-C. When statin intolerance or suboptimal lipid control persists, ezetimibe and PCSK9 inhibitors provide additive LDL-C reductions, further diminishing cardiovascular risk. Novel agents such as bempedoic acid and inclisiran have expanded the therapeutic arsenal, targeting cholesterol synthesis and PCSK9 production, respectively.

Antiplatelet therapy constitutes another pharmacological pillar. Low-dose aspirin, through irreversible cyclooxygenase-1 inhibition, reduces thromboxane-mediated platelet aggregation and is indicated for almost all patients with established IHD. In higher-risk settings-such as after percutaneous coronary intervention or acute coronary syndrome-dual antiplatelet therapy with a $P2Y_{12}$ inhibitor (clopidogrel, ticagrelor, or prasugrel) for at least six to twelve months significantly lowers the incidence of stent thrombosis and recurrent ischemic events. Select patients may benefit from prolonged therapy, guided by bleeding risk assessments. The introduction of low-dose rivaroxaban as an adjunct to aspirin

in stable atherosclerotic disease offers modest additional event reduction, albeit at the expense of increased bleeding.

Blood pressure control and diabetes management further guard against IHD. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers reduce afterload, inhibit remodeling, and confer renal protection in diabetic patients. Mineralocorticoid receptor antagonists, particularly in those with heart failure or left ventricular dysfunction, improve survival. Newer antidiabetic agents, such as SGLT2 inhibitors and GLP-1 receptor agonists, have demonstrated cardiovascular benefit beyond glycemic control, reducing rates of hospitalization and mortality in patients with diabetes and high cardiovascular risk.

Non-pharmacological prevention centers on lifestyle modification. A diet rich in fruits, vegetables, whole grains, lean proteins, and healthy fats-notably the Mediterranean diet-consistently correlates with lower cardiovascular events. Reducing saturated and trans fats, refined sugars, and sodium further enhances lipid and blood pressure profiles. Regular aerobic exercise-at least 150 minutes of moderate activity per week-improves endothelial function, raises high-density lipoprotein cholesterol, lowers blood pressure, and fosters insulin sensitivity. Resistance training and flexibility exercises complement cardiovascular workouts, supporting musculoskeletal health.

Smoking cessation yields immediate and long-term cardiovascular benefits: within weeks of quitting, endothelial function improves and platelet activation diminishes, while five-year abstinence halves mortality risk. Behavioral interventions, nicotine replacement, and pharmacotherapy (bupropion, varenicline) facilitate sustained cessation. Stress-management techniques-including cognitive behavioral therapy, mindfulness, and relaxation exercises-address the psychophysiological contributors to hypertension and unhealthy coping behaviors.

Individualized patient monitoring and management

A one-size-fits-all approach falls short in IHD care. Patient follow-up must adapt to each individual's clinical profile, comorbidities, and preferences. Initial post-discharge visits assess adherence to medications, tolerance of side effects, and achievement of targets for LDL-C, blood pressure, and HbA1c. Biomarkers such as high-sensitivity C-reactive protein and natriuretic peptides may inform residual risk and guide intensification of therapy.

Ambulatory monitoring-whether through periodic stress testing, Holter ECG, or wearable devices-detects silent ischemia and arrhythmias. For patients with borderline or evolving symptoms, stress echocardiography or nuclear perfusion scanning quantifies ischemic burden, informing decisions about revascularization versus continued medical therapy. In those with implanted devices, remote monitoring tracks arrhythmic events and heart failure parameters, enabling early intervention.

Cardiac rehabilitation programs offer structured exercise, education, and psychosocial support, improving functional capacity and reducing rehospitalizations. Tailoring rehabilitation intensity to baseline fitness, comorbid conditions, and patient motivation maximizes engagement and outcomes. Telehealth platforms and mobile applications facilitate remote coaching, symptom reporting, and medication reminders.

Risk stratification tools-such as the GRACE and TIMI scores in acute settings, or the SMART and Framingham scores for long-term risk-provide individualized prognostic estimates. High-risk patients may require more frequent visits, advanced imaging, or extended dual antiplatelet therapy, whereas low-risk individuals benefit from less intensive surveillance. Shared decision-making, incorporating patient values and quality-of-life considerations, guides therapy duration, invasive testing, and lifestyle goals.

Emerging preventive strategies and future directions

As understanding of IHD pathobiology deepens, novel preventive approaches emerge. Anti-inflammatory therapies targeting interleukin-1β (canakinumab) and colchicine-shown in large trials to reduce recurrent events-highlight the role of inflammation beyond lipid and hemodynamic factors. Gene therapy and RNA-based interventions hold promise for modulating lipid pathways, stabilizing plaques, and enhancing myocardial repair.

Advances in precision medicine leverage genetic, metabolomic, and proteomic data to identify patients who may derive exceptional benefit from specific interventions or who face higher risk of adverse effects. Personalized antiplatelet regimens guided by platelet function testing or genetic polymorphisms (e.g., CYP2C19 variants) optimize efficacy and safety.

Preventive cardiology increasingly integrates digital health tools. Wearable devices track heart rate variability, physical activity, and sleep patterns, offering real-time insights into patient behavior and physiologic responses. Artificial intelligence algorithms analyze large datasets to predict decompensation, personalize exercise prescriptions, and nudge healthier choices. Community-level interventions-such as tobacco taxation, creation of walkable neighborhoods, and public education on healthy diets-address social determinants of health that underpin IHD. Population screening for familial hypercholesterolemia and cascade testing in relatives enable early identification and treatment, preventing premature disease.

Prevention and patient follow-up in ischemic heart disease encompass a dynamic interplay of pharmacological therapy, lifestyle interventions, individualized monitoring, and emerging innovations. By addressing modifiable risk factors through tailored pharmacotherapy and behavioral change, maintaining vigilant long-term surveillance, and embracing precision medicine and digital health, clinicians can significantly reduce recurrent events, improve functional status, and extend survival. As new preventive strategies evolve, integrating

evidence-based therapies with patient-centered care will remain paramount in the fight against ischemic heart disease.

3.4. Cardiac rehabilitation and quality-of-life enhancement

Cardiac rehabilitation represents a comprehensive, multidisciplinary approach designed to support patients recovering from ischemic heart disease (IHD) and related acute coronary events. By combining structured exercise training, education, psychosocial support, and regular follow-up, rehabilitation programs aim not only to restore functional capacity but also to reduce subsequent cardiovascular risk and improve overall well-being. Modern guidelines endorse cardiac rehabilitation as a Class I recommendation for patients post-myocardial infarction, after revascularization procedures, and for those with chronic stable angina or heart failure due to IHD. Yet, despite clear evidence of its benefits, participation rates remain suboptimal globally, underscoring the need for enhanced delivery models and patient engagement strategies.

Multidisciplinary exercise-based rehabilitation programs

At the core of cardiac rehabilitation lies an individualized exercise prescription. Exercise physiologists and cardiologists collaborate to tailor programs that progressively challenge the patient's cardiovascular system while monitoring for ischemia, arrhythmia, or undue hemodynamic stress. Initial assessment typically includes a symptom-limited exercise test-whether treadmill or bicycle ergometry-to determine peak oxygen uptake (VO_2 peak), identify inducible ischemia, and establish safe training thresholds. Heart rate, blood pressure, ECG changes, and perceived exertion scales guide intensity, which is often prescribed at 40-70 percent of heart rate reserve or VO_2 peak, depending on baseline fitness and ventricular function.

Aerobic training-comprising walking, cycling, or treadmill work-forms the backbone of the regimen, aiming for at least 150 minutes of moderate-intensity

exercise per week. Sessions typically last 30-60 minutes, three to five times weekly, progressing from continuous to interval formats to maximize cardiovascular stimulus while allowing recovery. Resistance training complements aerobic work by preserving or increasing lean muscle mass, improving peripheral oxygen extraction, and enhancing metabolic control. Exercises targeting major muscle groups-leg press, chest press, and seated row-start at low loads (20-30 percent one-repetition maximum) with two to three sets of 10-15 repetitions, progressing gradually to 50-70 percent one-repetition maximum as tolerated.

Flexibility and balance exercises address joint mobility and fall prevention, particularly in elderly patients with comorbidities. Stretching major muscle groups and incorporating proprioceptive drills-such as tandem stance or single-leg balance-help maintain functional independence. A multidisciplinary team including physiotherapists, occupational therapists, and exercise physiologists ensures that the program aligns with the patient's comorbid conditions: diabetic neuropathy, osteoarthritis, or chronic obstructive pulmonary disease may necessitate exercise modifications.

Exercise sessions are conducted under medical supervision, with telemetry monitoring for high-risk individuals. Emergency protocols-defibrillator availability, trained staff, and rapid transfer pathways-mitigate the rare but serious risks of exercise-induced arrhythmias or ischemia. As patients progress, home-based exercise components reinforce habits, with wearable activity trackers and telemonitoring enhancing adherence and providing real-time feedback to the care team.

Clinical trials have demonstrated that participation in phase II (outpatient) cardiac rehabilitation reduces all-cause and cardiovascular mortality by approximately 20 percent, decreases rehospitalization rates, and improves exercise capacity by up to 25 percent. Improved endothelial function, enhanced autonomic balance (greater heart rate variability), and favorable modulation of inflammatory markers underlie these benefits. By increasing daily physical activity and breaking

sedentary patterns, exercise-based rehabilitation contributes to sustained lifestyle change and risk reduction.

Psychosocial support, patient education and lifestyle coaching

Physical recovery alone does not guarantee optimal long-term outcomes; psychosocial factors profoundly influence adherence, mood, and quality of life. Anxiety, depression, and social isolation are common after acute coronary syndromes and predict poorer cardiovascular and psychosocial outcomes. Integrating psychological support into rehabilitation addresses these challenges through stress management, counseling, and group interventions.

Cognitive behavioral therapy techniques help patients identify and modify maladaptive thought patterns-catastrophizing chest discomfort or excessive health anxiety-that may limit activity and perpetuate depressive symptoms. Relaxation training, including deep breathing exercises, progressive muscle relaxation, and guided imagery, reduces sympathetic overactivity and lowers blood pressure. Mindfulness-based stress reduction programs enhance emotional regulation and interoceptive awareness, enabling patients to distinguish benign sensations from warning signs of ischemia.

Peer support groups and facilitated group sessions foster social connectedness, reduce feelings of isolation, and provide opportunities for sharing coping strategies. Patients often find encouragement in hearing success stories from peers who have navigated similar challenges, enhancing self-efficacy and motivation.

Patient education covers the pathophysiology of IHD, the rationale for prescribed medications, and recognition of warning symptoms. Interactive workshops and multimedia resources teach safe exercise principles, medication adherence techniques, and emergency response (e.g., use of sublingual nitroglycerin or seeking prompt medical attention). Nutritional counseling by registered dietitians emphasizes heart-healthy patterns-Mediterranean or DASH

(Dietary Approaches to Stop Hypertension) diets-focusing on increased consumption of fruits, vegetables, whole grains, and lean proteins while minimizing processed foods, saturated fats, and sodium. Counseling is tailored to cultural preferences and socioeconomic realities, equipping patients with practical meal plans and strategies for dining out.

Smoking cessation support combines pharmacotherapy-nicotine replacement, bupropion, or varenicline-with behavioral counseling. Addressing triggers, relapse prevention, and maintenance of smoke-free status is critical, as smoking remains one of the most potent modifiable risk factors. Alcohol moderation, weight management, and sleep hygiene are also integral educational topics.

Lifestyle coaches or health coaches provide ongoing accountability through regular check-ins, goal setting, and problem solving. Motivational interviewing techniques help patients identify intrinsic motivations for change, enhancing engagement. Digital platforms-mobile apps, telehealth, and wearable devices-facilitate remote monitoring of activity, vital signs, and self-reported behaviors, enabling timely interventions and reinforcement of positive behaviors.

Assessment of functional capacity and health-related quality-of-life metrics

Objective assessment of functional capacity and patient-centered outcomes ensures that rehabilitation programs meet individual goals and supports continuous quality improvement. Peak exercise capacity, measured via cardiopulmonary exercise testing, provides a quantitative benchmark for VO_2 peak and anaerobic threshold. Improvements in these metrics correlate with enhanced survival and reduced hospitalization. For patients unable to undergo full exercise testing, submaximal tests (six-minute walk test, incremental shuttle walk test) offer feasible alternatives, with well-validated prognostic significance.

Peak METs (metabolic equivalent tasks) achieved during exercise testing inform risk stratification: each 1 MET increase associates with a 10-25 percent reduction in mortality. Tracking METs over time gauges response to rehabilitation and guides progression of exercise prescriptions. Periodic retesting-every three to six months-enables timely adjustments to training intensity and identifies patients requiring alternative interventions.

Health-related quality of life (HRQoL) is measured using standardized instruments such as the Seattle Angina Questionnaire, Kansas City Cardiomyopathy Questionnaire, or the SF-36 Health Survey. These tools assess domains including physical functioning, symptom burden, social functioning, and emotional well-being. By capturing patient perceptions of health status, HRQoL metrics illuminate aspects of recovery not reflected in physiological measures alone. Improvements in HRQoL scores following rehabilitation predict sustained adherence to therapy and lower rates of adverse cardiovascular events. Depression and anxiety scales-such as the Patient Health Questionnaire-9 or the Generalized Anxiety Disorder-7-screen for psychological distress. Identifying patients with elevated scores triggers targeted psychosocial interventions, which have been shown to yield parallel gains in HRQoL and functional capacity.

Digital health solutions enable continuous, real-world monitoring. Wearable sensors track daily step counts, heart rate patterns, and sleep quality, translating data into actionable insights for both patients and providers. Automated algorithms detect deviations from expected recovery trajectories-declining activity, rising resting heart rate-and prompt outreach. Telemonitoring reduces barriers to follow-up in geographically remote or mobility-limited patients, supporting long-term engagement.

Structured post-rehabilitation maintenance programs sustain benefits. Graduated transition from supervised to independent exercise-augmented by community-based resources such as walking groups or senior fitness classes-fosters lifelong physical activity. Ongoing education newsletters, web portals, and

mobile reminders reinforce medication adherence, lifestyle goals, and symptom vigilance. Quality assurance in cardiac rehabilitation involves benchmarking program outcomes-functional gains, HRQoL improvements, readmission rates-against established standards. Continuous feedback loops and periodic program audits drive enhancements in patient selection, resource allocation, and multidisciplinary collaboration.

CONCLUSION

This monograph has explored ischemic heart disease (IHD) from its molecular genesis through clinical manifestations to modern therapeutic and rehabilitative strategies. In Chapter I, we elucidated the cascade of endothelial dysfunction, lipid accumulation, and inflammatory processes that underpin atherosclerotic plaque formation and vessel narrowing. Genetic predispositions and environmental contributors—ranging from familial hypercholesterolemia to dietary patterns and stress—further modulate individual susceptibility, highlighting the need for both population-level prevention and personalized risk assessment.

Chapter II examined the heterogeneous clinical course of IHD, from silent ischemia detected only through ambulatory monitoring to exertional and variant angina, acute myocardial infarction, and the chronic sequelae of heart failure and arrhythmia. We detailed how early recognition of ischemic symptoms, combined with electrocardiography, advanced imaging, and biomarkers, enables timely intervention. Emphasis on disease staging clarified that stable presentations can evolve rapidly into high-risk acute coronary syndromes, underscoring the importance of vigilant surveillance and risk stratification.

In Chapter III, we reviewed therapeutic approaches that transform patient outcomes. Pharmacotherapy with β-blockers, statins, ACE inhibitors, and antithrombotic agents addresses the key pathophysiological pillars of IHD—reducing myocardial oxygen demand, stabilizing plaques, modulating neurohormonal activation, and preventing thrombosis. When medical management alone proves insufficient, percutaneous and surgical revascularization techniques offer durable relief of ischemia. Equally essential are comprehensive prevention and follow-up programs: lifestyle modification, lipid and blood pressure control, smoking cessation, and structured cardiac rehabilitation restore functional capacity and enhance quality of life.

Collectively, these chapters demonstrate that combating IHD demands an integrated, multidisciplinary strategy. Advances in molecular understanding pave

the way for novel therapies, while evolving diagnostic technologies sharpen our ability to detect disease at its earliest stages. Ultimately, the synergy of evidence-based medical, interventional, and rehabilitative measures—tailored to each patient's risk profile and clinical presentation—remains the foundation for reducing the global burden of ischemic heart disease. Continuous innovation, patient engagement, and robust healthcare systems will be vital to sustaining progress and improving outcomes for those affected by this pervasive cardiovascular condition.

REFERENCES

1. A.Gadayev. Ichki kasalliklar. - Toshkent: "Turon zamin ziyo", 2016. - 800 b.

2. Amsterdam E.A., Wenger N.K., Brindis R.G., et al. 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes // *Journal of the American College of Cardiology*. 2014. Vol. 64, No 24. P. e139-e228.

3. Braunwald E., Zipes D.P., Libby P., Bonow R.O. *Heart Disease: A Textbook of Cardiovascular Medicine*. 10th ed. Philadelphia: Elsevier Saunders, 2013. 2496 p.

4. Fuster V., Walsh R.A., Harrington R.A. *Hurst's The Heart*. 14th ed. New York: McGraw-Hill Education, 2017. 3168 p.

5. Giannuzzi P., Saner H., Björnstad H., et al. Secondary Prevention Through Cardiac Rehabilitation: Position Paper of the Study Group on Rehabilitation, Exercise, and Implantable Devices of the European Society of Cardiology // *European Heart Journal*. 2003. Vol. 24, No 13. P. 1273-1278.

6. Ibanez B., James S., Agewall S., et al. 2017 ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation // *European Heart Journal*. 2018. Vol. 39, No 2. P. 119-177.

7. Neumann F.-J., Sousa-Uva M., Ahlsson A., et al. 2018 ESC/EACTS Guidelines on Myocardial Revascularization // *European Heart Journal*. 2019. Vol. 40, No 2. P. 87-165.

8. Qosimova N.A. "Yurak ishemik kasalligi bilan bemorlarda koronar arteriyalar shikastlanishi va lipid profil darajasining o'zaro bog'liqligi". Экономика и социум. 5-1(96), 2022.

9. Smith S.C. Jr., Benjamin E.J., Bonow R.O., et al. AHA/ACC Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update // *Journal of the American College of Cardiology*. 2011. Vol. 58, No 23. P. 2432-2446.

10. Smith, J. et al. (2022). Epidemiology of Ischemic Heart Disease. Journal of Cardiology, 78(5), 312-321.

11. Stone P.H., Raizner A.E., Rihal C.S., et al. Bivalirudin Plus Provisional Glycoprotein IIb/IIIa Inhibitor Versus Heparin Plus Planned Glycoprotein IIb/IIIa Inhibitor During Percutaneous Coronary Intervention: Evaluation of Platelet IIb/IIIa Receptor Inhibition and Benefit // *Journal of the American College of Cardiology*. 2006. Vol. 47, No 1. P. 65-71.

12. Wenger N.K., Froelicher E.S., Smith L.K., et al. Cardiac Rehabilitation as Secondary Prevention // *Agency for Health Care Policy and Research*. Clinical Practice Guidelines, No 96-0672. Rockville, MD: U.S. Department of Health and Human Services, 1995. 300 p.

13. П. Х. Кардиомиопатии и миокардиты. - М., 2000. - 128 с.

14. Поздняков Ю.М., Волков В.С. Стенокардия. Москва, 2006.